Marc Goodman
Stock Analyst at Leerink Partners
(2.94)
# 1,648
Out of 5,090 analysts
94
Total ratings
57.33%
Success rate
28.61%
Average return
Main Sectors:
Stocks Rated by Marc Goodman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MPLT MapLight Therapeutics | Initiates: Outperform | $30 | $18.49 | +62.25% | 1 | Nov 21, 2025 | |
| OVID Ovid Therapeutics | Initiates: Outperform | $5 | $1.67 | +199.40% | 1 | Nov 17, 2025 | |
| AVDL Avadel Pharmaceuticals | Downgrades: Market Perform | $19 | $21.34 | -13.31% | 3 | Oct 23, 2025 | |
| LBRX LB Pharmaceuticals | Initiates: Outperform | $34 | $19.50 | +74.36% | 1 | Oct 6, 2025 | |
| BHVN Biohaven | Maintains: Outperform | $60 → $50 | $9.55 | +423.56% | 7 | Aug 12, 2025 | |
| AMLX Amylyx Pharmaceuticals | Upgrades: Outperform | $4 → $10 | $14.20 | -29.58% | 5 | May 7, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $110 → $150 | $149.22 | +0.52% | 7 | Feb 10, 2025 | |
| RLMD Relmada Therapeutics | Downgrades: Market Perform | $10 → $1 | $4.24 | -76.42% | 3 | Dec 4, 2024 | |
| LENZ LENZ Therapeutics | Initiates: Outperform | $32 | $26.72 | +19.76% | 1 | Apr 15, 2024 | |
| BLTE Belite Bio | Initiates: Outperform | $25 | $150.00 | -83.33% | 1 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $19.96 | +150.50% | 1 | Jan 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $20 | $6.85 | +191.97% | 3 | Jan 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $100 → $115 | $155.51 | -26.05% | 4 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $270 → $310 | $181.30 | +70.99% | 11 | Oct 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $46 | $45.01 | +2.20% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $21 | $27.44 | -23.47% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $200 → $210 | $169.70 | +23.75% | 5 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $2.80 | +257.14% | 2 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $24 → $27 | $29.52 | -8.54% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $15 | $4.70 | +219.15% | 2 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $270 | $601.50 | -55.11% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $79 → $96 | $226.08 | -57.54% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $52.15 | - | 2 | May 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $67 | $99.72 | -32.81% | 3 | Oct 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $98 | $13.44 | +629.17% | 7 | Oct 5, 2017 |
MapLight Therapeutics
Nov 21, 2025
Initiates: Outperform
Price Target: $30
Current: $18.49
Upside: +62.25%
Ovid Therapeutics
Nov 17, 2025
Initiates: Outperform
Price Target: $5
Current: $1.67
Upside: +199.40%
Avadel Pharmaceuticals
Oct 23, 2025
Downgrades: Market Perform
Price Target: $19
Current: $21.34
Upside: -13.31%
LB Pharmaceuticals
Oct 6, 2025
Initiates: Outperform
Price Target: $34
Current: $19.50
Upside: +74.36%
Biohaven
Aug 12, 2025
Maintains: Outperform
Price Target: $60 → $50
Current: $9.55
Upside: +423.56%
Amylyx Pharmaceuticals
May 7, 2025
Upgrades: Outperform
Price Target: $4 → $10
Current: $14.20
Upside: -29.58%
Axsome Therapeutics
Feb 10, 2025
Maintains: Outperform
Price Target: $110 → $150
Current: $149.22
Upside: +0.52%
Relmada Therapeutics
Dec 4, 2024
Downgrades: Market Perform
Price Target: $10 → $1
Current: $4.24
Upside: -76.42%
LENZ Therapeutics
Apr 15, 2024
Initiates: Outperform
Price Target: $32
Current: $26.72
Upside: +19.76%
Belite Bio
Jul 26, 2023
Initiates: Outperform
Price Target: $25
Current: $150.00
Upside: -83.33%
Jan 30, 2023
Initiates: Outperform
Price Target: $50
Current: $19.96
Upside: +150.50%
Jan 19, 2023
Maintains: Outperform
Price Target: $18 → $20
Current: $6.85
Upside: +191.97%
Nov 2, 2022
Maintains: Market Perform
Price Target: $100 → $115
Current: $155.51
Upside: -26.05%
Oct 26, 2022
Maintains: Outperform
Price Target: $270 → $310
Current: $181.30
Upside: +70.99%
Aug 11, 2022
Maintains: Outperform
Price Target: $40 → $46
Current: $45.01
Upside: +2.20%
Aug 9, 2022
Maintains: Outperform
Price Target: $27 → $21
Current: $27.44
Upside: -23.47%
Aug 4, 2022
Maintains: Outperform
Price Target: $200 → $210
Current: $169.70
Upside: +23.75%
Jul 11, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $2.80
Upside: +257.14%
Apr 28, 2022
Maintains: Market Perform
Price Target: $24 → $27
Current: $29.52
Upside: -8.54%
Dec 21, 2021
Maintains: Outperform
Price Target: $24 → $15
Current: $4.70
Upside: +219.15%
Mar 13, 2020
Maintains: Buy
Price Target: $300 → $270
Current: $601.50
Upside: -55.11%
Nov 19, 2019
Maintains: Buy
Price Target: $79 → $96
Current: $226.08
Upside: -57.54%
May 21, 2018
Downgrades: Neutral
Price Target: n/a
Current: $52.15
Upside: -
Oct 30, 2017
Maintains: Buy
Price Target: $72 → $67
Current: $99.72
Upside: -32.81%
Oct 5, 2017
Maintains: Buy
Price Target: $84 → $98
Current: $13.44
Upside: +629.17%